Several prospective and retrospective studies have shown that genotypic testing for drug-
resistant HIV-1 variants has helped health-care providers better understand patient …

Genotypic assays to detect HIV drug resistance are recommended for use in the routine
clinical care of HIV-infected persons. Genotypic resistance assays have demonstrated good …

Minor drug-resistant variants exist in every patient infected with human immunodeficiency
virus (HIV). Because these minority variants are usually present at very low levels, they …

The International AIDS Society–USA (IAS–USA) Drug Resistance Mutations Group is
marking 6 years as an independent volunteer panel of experts focused on identifying key …

Human immunodeficiency virus type 1 (HIV-1) drug resistance genotyping is recommended
to help in the selection of antiretroviral therapy and to prevent virologic failure. There are …

accepted 1 December 2009; electronically published 26 January 2010. Potential conflicts of
interest: WH is named on a patent application on the use of the real-time polymerase chain …

With drug-resistant HIV-1 present in at least 10%–20% of new infections in Western
countries and in> 60% of patients failing antiretroviral therapy (ART), monitoring HIV-1 drug …

Infection with drug-resistant HIV-1 may result from the acquisition of mutant strains or from
their selection within the individual; either can compromise the efficacy of antiretroviral …

Technologic advances in human immunodeficiency virus type 1 (HIV-1) sequencing have
revolutionized the study of antiretroviral drug resistance and are increasingly moving from …

This version of the International AIDS Society–USA (IAS-USA) Drug Resistance Mutations
Figures updates the figures published in this journal in August/September 2006. 1 The IAS …